⚠ Evidence warning: Clinical trials or other evidence do not support the claim that biofeedback and autogenic training are effective in primary Raynaud's. This page keeps it as a report of what people, websites or other media say.

Cold Hands and Feet

3D hand illustration showing white, blue and red fingertips
A white-blue-red three-phase colour change points strongly to Raynaud's phenomenon
Infographic of three mechanisms behind cold hands and feet
Cold extremities come from reduced warm blood flow to the digits, reduced metabolic heat production, or both
Close-up of nailfold capillary loops, some enlarged
In scleroderma, nailfold capillaroscopy can reveal capillary dropout, giant capillaries and avascular areas

Table of Contents

  1. Overview
  2. Types
  3. Common Causes
  4. Mechanisms
  5. Evaluation
  6. Management
  7. Signs That Point to a Serious Cause
  8. Connections
  9. Key Research Papers
  10. Featured Videos

Overview

Cold hands and feet span a spectrum from benign vasoconstriction — a chilly room, low body fat, anxiety, or simple physiological cold sensitivity — all the way to vascular disease and connective tissue disease. Most people experience cold extremities occasionally without any underlying pathology, but persistent or asymmetric cold extremities are the pattern clinicians investigate. The clinical triad to assess is straightforward: color change (a white-blue-red triphasic pattern points strongly to Raynaud's phenomenon), pulses (absent or diminished pulses suggest peripheral artery disease), and associated systemic features (cold intolerance with fatigue, weight gain, and dry skin suggests hypothyroidism; cold extremities with pallor and exertional dyspnea suggest anemia). Onset after age 40, asymmetric symptoms, digital ulceration, or systemic features such as joint pain, rash, or dysphagia all raise the probability of a secondary cause that requires specific treatment.

Primary Raynaud's itself is common. A 2015 pooled analysis of 33 observational studies (33,733 people) put it at 4.85% of the general population, with about 0.25% of people developing it each year. Family history had the strongest link (odds ratio 16.6), followed by migraine (4.02), manual work (2.66), female sex (1.65) and smoking (1.27). The definition of primary Raynaud's varied considerably between the studies.

Types

Common Causes

Mechanisms

Cold extremities reflect either reduced delivery of warm blood to the skin and digits, reduced metabolic heat production, or both. Most patients have one dominant mechanism:

Evaluation

Workup is guided by age of onset, symmetry, presence of triphasic color change, and any systemic features. A reasonable starting set includes:

Management

Signs That Point to a Serious Cause

Connections

Key Research Papers

Historical Background

The phenomenon now bearing his name was first described by French medical student Maurice Raynaud in his 1862 doctoral thesis De l'asphyxie locale et de la gangrène symétrique des extrémités, in which he documented twenty-five cases of episodic digital ischemia and proposed an autonomic-nervous-system origin. Edgar Allen described his bedside test of radial and ulnar arch patency in 1929, providing the first reproducible method to assess hand circulation at the bedside. Pharmacologic management began in earnest in the 1980s when nifedipine was shown to reduce attack frequency in primary Raynaud's; in subsequent decades, bosentan and intravenous iloprost transformed the management of digital ulcers in systemic sclerosis. The 2013 ACR/EULAR classification criteria for systemic sclerosis allowed earlier and more reproducible identification of secondary Raynaud's, while nailfold capillaroscopy moved from research tool to routine office procedure.

Key Research Papers

  1. Wigley FM. Clinical practice. Raynaud's phenomenon. New England Journal of Medicine. 2002;347(13):1001-1008. — doi:10.1056/NEJMcp013013
  2. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases. 2013;72(11):1747-1755. — doi:10.1136/annrheumdis-2013-204424
  3. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases. 2017;76(8):1327-1339. — doi:10.1136/annrheumdis-2016-209909
  4. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis & Rheumatism. 2004;50(12):3985-3993. — doi:10.1002/art.20676
  5. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2017;135(12):e726-e779. — doi:10.1161/CIR.0000000000000471
  6. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases. European Heart Journal. 2018;39(9):763-816. — doi:10.1093/eurheartj/ehx095
  7. Belch JJ, Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs. 1996;52(5):682-695. — doi:10.2165/00003495-199652050-00006
  8. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology. 2005;44(2):145-150. — doi:10.1093/rheumatology/keh390
  9. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nature Reviews Rheumatology. 2012;8(8):469-479. — doi:10.1038/nrrheum.2012.96
  10. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clinic Proceedings. 2010;85(7):678-692. — doi:10.4065/mcp.2010.0133
  11. Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2016;2(2):CD002069. — PubMed PMID: 26914257
  12. Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database Syst Rev. 2017;12(12):CD000467. — PubMed PMID: 29237099
  13. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160(8):1101-1108. — PubMed PMID: 10789602
  14. Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5(3):e006389. — PubMed PMID: 25776043
  15. Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021;5(5):CD006687. — PubMed PMID: 33998674
  16. Hlavaty A, Dari L, Cracowski JL, et al. Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. Arthritis Rheumatol. 2026;78(4):985-992. — PubMed PMID: 41261736
  17. Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. Circulation. 2024;149(24):e1313-e1410. — PubMed PMID: 38743805
  18. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40. — PubMed PMID: 39874231
  19. Sharifzadeh A, Smith GP. An Evidence-Based Review of Perniosis (Chilblains): Therapeutic Strategies and Integration With Raynaud's Syndrome Management. Int J Dermatol. 2025;64(10):1781-1787. — PubMed PMID: 40272049
  20. Argobi Y. Trends and Associations of Chilblains Prevalence with Connective Tissue Diseases, Including COVID-19 Incidence. Clin Cosmet Investig Dermatol. 2025;18:339-344. — PubMed PMID: 39911214

PubMed Topic Searches

  1. PubMed: Raynaud phenomenon pathogenesis
  2. PubMed: Systemic sclerosis and digital ulcers
  3. PubMed: Peripheral artery disease diagnosis and management
  4. PubMed: Nailfold capillaroscopy in scleroderma
  5. PubMed: Hypothyroidism and cold intolerance
  6. PubMed: Thromboangiitis obliterans (Buerger's disease)

Back to Table of Contents

Cold Hands Feet — scientific infographic poster